ERA-话题@MedSci

#ERA#

425篇内容 | 3168人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1738991, encodeId=8e371e389910f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=2019 ERAS建议：剖宫产术后护理指南, objectType=article, longId=185214, objectId=702b185214db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=702b185214db, replyNumber=0, likeNumber=13, createdTime=2020-02-15, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=702b185214db, moduleTitle=2019 ERAS建议：剖宫产术后护理指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=702b185214db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1739006, encodeId=0cdb1e39006d1, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=礼来与AbCellera宣布合作开发针对COVID-19新型冠状病毒的抗体, objectType=article, longId=190005, objectId=61fa1900054e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61fa1900054e, replyNumber=0, likeNumber=75, createdTime=2020-08-22, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61fa1900054e, moduleTitle=礼来与AbCellera宣布合作开发针对COVID-19新型冠状病毒的抗体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61fa1900054e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738976, encodeId=68dc1e389769f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Verastem的PI3K抑制剂COPIKTRA治疗T细胞淋巴瘤，获得FDA的孤儿药称号, objectType=article, longId=180514, objectId=7f23180514e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f23180514e5, replyNumber=0, likeNumber=84, createdTime=2020-08-17, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f23180514e5, moduleTitle=Verastem的PI3K抑制剂COPIKTRA治疗T细胞淋巴瘤，获得FDA的孤儿药称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f23180514e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738981, encodeId=d8c11e38981aa, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Mallinckrodt的UVADEX（甲氧沙林）获得澳大利亚批准，与THERAKOS CELLEX光电穿刺系统联合治疗成人慢性移植物抗宿主疾病和T细胞淋巴瘤, objectType=article, longId=182364, objectId=2e5e18236425, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e5e18236425, replyNumber=0, likeNumber=76, createdTime=2020-09-15, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e5e18236425, moduleTitle=Mallinckrodt的UVADEX（甲氧沙林）获得澳大利亚批准，与THERAKOS CELLEX光电穿刺系统联合治疗成人慢性移植物抗宿主疾病和T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e5e18236425)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738985, encodeId=99d51e38985bd, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Levo Therapeutics的鼻内卡贝缩宫素治疗Prader-Willi综合症，获得FDA的快速通道指定, objectType=article, longId=183450, objectId=33641834504d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33641834504d, replyNumber=0, likeNumber=61, createdTime=2019-12-08, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33641834504d, moduleTitle=Levo Therapeutics的鼻内卡贝缩宫素治疗Prader-Willi综合症，获得FDA的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33641834504d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738996, encodeId=a99f1e3899606, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Northsea Therapeutics融资4000万美元开发鱼油衍生物，治疗非酒精性脂肪性肝炎, objectType=article, longId=186009, objectId=83751860095e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83751860095e, replyNumber=0, likeNumber=50, createdTime=2020-01-29, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83751860095e, moduleTitle=Northsea Therapeutics融资4000万美元开发鱼油衍生物，治疗非酒精性脂肪性肝炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83751860095e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738978, encodeId=cb101e38978dc, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Immunotherapy：舌下免疫治疗对屋尘螨诱导的过敏性鼻炎和并发症的疗效分析, objectType=article, longId=181817, objectId=b31c18181e40, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b31c18181e40, replyNumber=0, likeNumber=63, createdTime=2020-04-29, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b31c18181e40, moduleTitle=Immunotherapy：舌下免疫治疗对屋尘螨诱导的过敏性鼻炎和并发症的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b31c18181e40)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1739005, encodeId=53751e390055a, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Physiotherapy：高渗盐水雾化结合呼气振荡性正压对囊性纤维化痰痰及相关症状的影响, objectType=article, longId=188442, objectId=7f8f18844266, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f8f18844266, replyNumber=0, likeNumber=95, createdTime=2020-05-29, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f8f18844266, moduleTitle=Physiotherapy：高渗盐水雾化结合呼气振荡性正压对囊性纤维化痰痰及相关症状的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f8f18844266)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738966, encodeId=cf731e3896678, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=NICE推荐将激酶抑制剂neratinib用作乳腺癌的新辅助治疗, objectType=article, longId=177327, objectId=749f1e732700, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=749f1e732700, replyNumber=0, likeNumber=67, createdTime=2019-10-20, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=749f1e732700, moduleTitle=NICE推荐将激酶抑制剂neratinib用作乳腺癌的新辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=749f1e732700)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738944, encodeId=b3ad1e389446a, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Stem Cell Research & Therapy：联合移植技术让基因治疗成为A型血友病更具前景的治疗方法, objectType=article, longId=163066, objectId=e23b163066a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e23b163066a2, replyNumber=0, likeNumber=87, createdTime=2020-01-30, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e23b163066a2, moduleTitle=Stem Cell Research & Therapy：联合移植技术让基因治疗成为A型血友病更具前景的治疗方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e23b163066a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738951, encodeId=12af1e3895164, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=AAN：Magenta Therapeutics的干细胞疗法MGTA-456的2期临床数据喜人, objectType=article, longId=165895, objectId=49e916589568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49e916589568, replyNumber=0, likeNumber=57, createdTime=2020-04-05, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49e916589568, moduleTitle=AAN：Magenta Therapeutics的干细胞疗法MGTA-456的2期临床数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49e916589568)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738968, encodeId=ea5b1e3896839, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Immunotherapy：MiR-146a类似物能够减轻过敏性鼻炎, objectType=article, longId=177724, objectId=0bda1e7724ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bda1e7724ea, replyNumber=0, likeNumber=73, createdTime=2020-05-07, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bda1e7724ea, moduleTitle=Immunotherapy：MiR-146a类似物能够减轻过敏性鼻炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bda1e7724ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738942, encodeId=fba21e3894256, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Theranostics：固定化钙三醇的微孔多糖多层包覆BCP复合支架可促进骨质疏松骨再生, objectType=article, longId=162467, objectId=fdd416246eec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdd416246eec, replyNumber=0, likeNumber=53, createdTime=2019-07-04, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdd416246eec, moduleTitle=Theranostics：固定化钙三醇的微孔多糖多层包覆BCP复合支架可促进骨质疏松骨再生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdd416246eec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738990, encodeId=3c6a1e38990c9, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Abeona Therapeutics的ABO-102基因疗法治疗罕见病，获得欧洲药品管理局的PRIME指定, objectType=article, longId=185054, objectId=f497185054c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f497185054c2, replyNumber=0, likeNumber=46, createdTime=2020-10-11, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f497185054c2, moduleTitle=Abeona Therapeutics的ABO-102基因疗法治疗罕见病，获得欧洲药品管理局的PRIME指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f497185054c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738939, encodeId=9fd01e38939df, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=OSE Immunotherapeutics的免疫检查点抑制剂： SIRPα单抗BI 765063获批在晚期实体瘤患者中进行1期临床研究, objectType=article, longId=161788, objectId=2b6a161e88d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b6a161e88d5, replyNumber=0, likeNumber=69, createdTime=2019-03-27, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b6a161e88d5, moduleTitle=OSE Immunotherapeutics的免疫检查点抑制剂： SIRPα单抗BI 765063获批在晚期实体瘤患者中进行1期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b6a161e88d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738953, encodeId=f90b1e3895371, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=构建导航护士在ERAS 腹腔镜肝切除术中的管理路径 | 护患沟通我有一套, objectType=article, longId=166201, objectId=993e166201a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=993e166201a6, replyNumber=0, likeNumber=40, createdTime=2019-07-07, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=993e166201a6, moduleTitle=构建导航护士在ERAS 腹腔镜肝切除术中的管理路径 | 护患沟通我有一套, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=993e166201a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738949, encodeId=008a1e3894940, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Theranostics：发现肺腺癌转移和耐药的新机制, objectType=article, longId=164832, objectId=2aa41648328e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2aa41648328e, replyNumber=0, likeNumber=70, createdTime=2019-10-16, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2aa41648328e, moduleTitle=Theranostics：发现肺腺癌转移和耐药的新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2aa41648328e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738965, encodeId=b5661e3896552, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=MC2 Therapeutics完成了MC2-01治疗斑块型银屑病患者欧盟III期头对头研究的患者入组, objectType=article, longId=177305, objectId=15131e730596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15131e730596, replyNumber=0, likeNumber=70, createdTime=2019-12-21, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15131e730596, moduleTitle=MC2 Therapeutics完成了MC2-01治疗斑块型银屑病患者欧盟III期头对头研究的患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15131e730596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738941, encodeId=75ef1e38941fb, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Curr HIV Res：药物不耐受转换为Eviplera®药物治疗后患者的表现, objectType=article, longId=162394, objectId=2e1b162394a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e1b162394a7, replyNumber=0, likeNumber=47, createdTime=2019-11-12, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e1b162394a7, moduleTitle=Curr HIV Res：药物不耐受转换为Eviplera®药物治疗后患者的表现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e1b162394a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738954, encodeId=4cc11e3895487, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Be The Match BioTherapies和Kiadis Pharma宣布战略合作以加速造血干细胞移植疗法, objectType=article, longId=166721, objectId=b315166e2142, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b315166e2142, replyNumber=0, likeNumber=73, createdTime=2019-07-20, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b315166e2142, moduleTitle=Be The Match BioTherapies和Kiadis Pharma宣布战略合作以加速造血干细胞移植疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b315166e2142)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ERA

2020-05-29

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

2019 ERAS建议：剖宫产术后护理指南

2020-02-15

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

礼来与AbCellera宣布合作开发针对COVID-19新型冠状病毒的抗体

2020-08-22

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Verastem的PI3K抑制剂COPIKTRA治疗T细胞淋巴瘤，获得FDA的孤儿药称号

2020-08-17

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Mallinckrodt的UVADEX（甲氧沙林）获得澳大利亚批准，与THERAKOS CELLEX光电穿刺系统联合治疗成人慢性移植物抗宿主疾病和T细胞淋巴瘤

2020-09-15

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Levo Therapeutics的鼻内卡贝缩宫素治疗Prader-Willi综合症，获得FDA的快速通道指定

2019-12-08

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Northsea Therapeutics融资4000万美元开发鱼油衍生物，治疗非酒精性脂肪性肝炎

2020-01-29

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Immunotherapy：舌下免疫治疗对屋尘螨诱导的过敏性鼻炎和并发症的疗效分析

2020-04-29

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Physiotherapy：高渗盐水雾化结合呼气振荡性正压对囊性纤维化痰痰及相关症状的影响

2020-05-29

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

NICE推荐将激酶抑制剂neratinib用作乳腺癌的新辅助治疗

2019-10-20

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Stem Cell Research & Therapy：联合移植技术让基因治疗成为A型血友病更具前景的治疗方法

2020-01-30

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

AAN：Magenta Therapeutics的干细胞疗法MGTA-456的2期临床数据喜人

2020-04-05

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Immunotherapy：MiR-146a类似物能够减轻过敏性鼻炎

2020-05-07

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Theranostics：固定化钙三醇的微孔多糖多层包覆BCP复合支架可促进骨质疏松骨再生

2019-07-04

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Abeona Therapeutics的ABO-102基因疗法治疗罕见病，获得欧洲药品管理局的PRIME指定

2020-10-11

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

OSE Immunotherapeutics的免疫检查点抑制剂： SIRPα单抗BI 765063获批在晚期实体瘤患者中进行1期临床研究

2019-03-27

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

构建导航护士在ERAS 腹腔镜肝切除术中的管理路径 | 护患沟通我有一套

2019-07-07

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Theranostics：发现肺腺癌转移和耐药的新机制

2019-10-16

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

MC2 Therapeutics完成了MC2-01治疗斑块型银屑病患者欧盟III期头对头研究的患者入组

2019-12-21

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Curr HIV Res：药物不耐受转换为Eviplera®药物治疗后患者的表现

2019-11-12

仁医06 (审核中...)

前往app查看评论内容

#ERA#

Be The Match BioTherapies和Kiadis Pharma宣布战略合作以加速造血干细胞移植疗法

2019-07-20

科室
- - 订阅+
  - 更多科室
工具
服务